Biogen revealed that a formal process is now underway to “evaluate strategic options” for its biosimilars business, pointing to a potential transfer of the unit to a new owner.
Biogen is considering selling its biosimilars business to a new owner, as part of a strategic review of the unit that has been formally kicked off by the former Samsung Bioepis joint venture partner.
While Biogen in early 2022 agreed to sell its stake in Samsung Bioepis to partner Samsung Biologics (see sidebar) –...
As Alvotech announced first-half results that outpaced expectations, the biosimilars developer’s management explained that the firm was targeting value and product margin over market share and volumes.
Roche and its Genentech subsidiary have sued Shanghai Henlius Biotech and commercialization partner Organon in the US, alleging infringement of 24 patents covering Perjeta (pertuzumab). The litigation follows Roche’s recent disclosure that biosimilars to Perjeta could launch as soon as 2026.
Boasting the “lowest WAC price among branded biosimilars to Stelara”, Accord BioPharma has launched its Imuldosa version of ustekinumab in the US at a 92% discount to the blockbuster immunology brand.
With H1 revenues not even hitting double-digits, Formycon is bidding on partnerships and royalties to generate at least €46m over the next half-year to reach its revenue goal.
Shortly after filing its lead candidate for ADHD through the FDA’s 505(b)(2) hybrid new drug application pathway, Cingulate has appointed interim leadership after placing chairman and CEO Shane Schaffer on administrative leave over legal matters unrelated to the company.
Roche and its Genentech subsidiary have sued Shanghai Henlius Biotech and commercialization partner Organon in the US, alleging infringement of 24 patents covering Perjeta (pertuzumab). The litigation follows Roche’s recent disclosure that biosimilars to Perjeta could launch as soon as 2026.
Boasting the “lowest WAC price among branded biosimilars to Stelara”, Accord BioPharma has launched its Imuldosa version of ustekinumab in the US at a 92% discount to the blockbuster immunology brand.
